Skip to main content
SpringerLink
Log in

Minimising peripheral neuropathy in patients treated with HAART

  • Drug reactions and interactions
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Carpenter CJC, Fischi MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1997. JAMA 1997; 277: 1962–9

    Article  PubMed  CAS  Google Scholar 

  2. Moyle GJ, Sadler M. Peripheral neuropathy with nucleoside antiretroviral. Risk factors, incidence and management. Drug Safety 1998; 19(6); 481–494

    Article  PubMed  CAS  Google Scholar 

  3. British National Formulary. No. 38. London: The Pharmaceutical Press, 1999 Sep: 283-5

  4. Kahn JO, Lagakos SW, Richman DD, et al. A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. N Engl J Med 1992; 327: 581–7

    Article  PubMed  CAS  Google Scholar 

  5. Gottlieb M, Peterson D, Adler M. Comparison of safety and efficacy of 2 doses of stavudine (Zerit, stavudine) in a large simple trial in the US parallel track program [abstract no. 1171]. 35th ICAAC: 1995 Sept 17-20, San Francisco: 235

  6. Alpha International Coordinating Committee. The Alpha trial: European/Australian randomised double-blind trial of two-doses of didanosine in zidovudine intolerant patients with symptomatic HIV disease. AIDS 1996; 10: 867–80

    Article  Google Scholar 

  7. Hammer SM, Katzenstein DA, Hughes MD, et al. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. N Engl J Med 1996; 335(15): 1081–90

    Article  PubMed  CAS  Google Scholar 

  8. Haubrich, Laerari J, Follansbee SE, et al. Improved survival and reduced disease progression in HIV-infected patients with advanced disease treated with saquinavir plus zalcitabine. Antiviral Ther 1998; 3: 33–42

    CAS  Google Scholar 

  9. Stellbrink H-J, the Invirase International Phase III trial (SV 14604) Group. Clinical and survival benefit of saquinavir (SQV) in combination with zalcitabine (ddC) and zidovudine (ZDV) in untreated/minimally treated HIV-infected patients [abstract 212]. Sixth European Conference on Clinical Aspects and Treatment of HIV infection: 1997 Oct 11–15, Hamburg: 21

    Google Scholar 

  10. Pollard RB, Petersen D, Hardy D, et al. Randomised double-blind study of combination therapy with didanosine and stavudine in HIV-infected individuals. Antiviral Ther 1997; 2 Suppl. 3: 89–93

    CAS  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Minimising peripheral neuropathy in patients treated with HAART. Drugs Ther. Perspect 15, 11–13 (2000). https://doi.org/10.2165/00042310-200015010-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-200015010-00004

Keywords

Search

Navigation